John Mooney - NeoGenomics Chief Officer
| NEO Stock | USD 16.93 0.54 3.29% |
Insider
John Mooney is Chief Officer of NeoGenomics
| Address | 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912 |
| Phone | 239 768 0600 |
| Web | https://www.neogenomics.com |
NeoGenomics Management Efficiency
The company has Return on Asset of (0.0276) % which means that on every $100 spent on assets, it lost $0.0276. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0838) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.12. In addition to that, Return On Capital Employed is likely to grow to -0.06. At this time, NeoGenomics' Fixed Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| Paul Changelian | Aclaris Therapeutics | N/A | |
| Niamh Murphy | ICON PLC | N/A | |
| Joseph Monahan | Aclaris Therapeutics | 67 | |
| Pamela Wong | Myriad Genetics | 56 | |
| Robert Hauzie | Sotera Health Co | N/A | |
| Lehmann JD | Sotera Health Co | 56 | |
| James Loerop | Aclaris Therapeutics | 59 | |
| Kevin Haas | Myriad Genetics | 38 | |
| Marcel Konrad | Caredx Inc | 48 | |
| Thomas Theuringer | Qiagen NV | N/A | |
| Kevin Yankton | Twist Bioscience Corp | 57 | |
| Siyuan Chen | Twist Bioscience Corp | N/A | |
| Matt Stauffer | Biodesix | N/A | |
| Sally Turner | Sotera Health Co | N/A | |
| Michael Biehl | Sotera Health Co | 68 | |
| Julie Mann | Neogen | 59 | |
| Michael Petras | Sotera Health Co | 55 | |
| Natalie Munk | Myriad Genetics | 43 | |
| Ian Anderson | Aclaris Therapeutics | N/A | |
| Marica Grskovic | Caredx Inc | N/A | |
| Rishi Kacker | Natera Inc | N/A | |
Management Performance
| Return On Equity | -0.0838 | ||||
| Return On Asset | -0.0276 |
NeoGenomics Leadership Team
Elected by the shareholders, the NeoGenomics' board of directors comprises two types of representatives: NeoGenomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeoGenomics. The board's role is to monitor NeoGenomics' management team and ensure that shareholders' interests are well served. NeoGenomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeoGenomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Bonello, Vice President of Strategy - Corporate Development and Investor Relations | ||
| Facmg MBA, Pres Officer | ||
| George Cardoza, Pres Operations | ||
| Warren Stone, President Division | ||
| Gary Passman, Chief Officer | ||
| Vishal Sikri, President Diagnostics | ||
| Alicia Olivo, General Development | ||
| JD Esq, President Informatics | ||
| Ali Olivio, Gen Sec | ||
| Cynthia Dieter, Chief Officer | ||
| Fernando LpezDaz, Director Science | ||
| Christopher BSc, CEO Director | ||
| Charlie Eidson, Director Devel | ||
| Kendra Sweeney, Vice Communications | ||
| Derek MD, Chief Officer | ||
| Hutan JD, Chief Officer | ||
| Kathryn McKenzie, Principal Accounting Officer, Vice President - Finance | ||
| Gregory Aunan, Senior Officer | ||
| John Mooney, Chief Officer | ||
| Greg Sparks, Chief Officer | ||
| Jeffrey MBA, Chief Officer |
NeoGenomics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeoGenomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0838 | ||||
| Return On Asset | -0.0276 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 2.32 B | ||||
| Shares Outstanding | 128.36 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 99.63 % | ||||
| Number Of Shares Shorted | 4.24 M | ||||
| Price To Earning | 272.37 X |
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving against NeoGenomics Stock
| 0.86 | HCM | HUTCHMED DRC | PairCorr |
| 0.85 | FLGC | Flora Growth Corp | PairCorr |
| 0.6 | AQB | AquaBounty Technologies | PairCorr |
| 0.59 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.57 | VRDN | Viridian Therapeutics | PairCorr |
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.